Fundraising FoxAlloplex Biotherapeutics
Boston, US · Delaware corporation · 3 known investors
Find your way into Alloplex Biotherapeutics
160 people in our graph share verified history with the Alloplex Biotherapeutics team — schools, employers, funds. One of them is your warm intro.
Alloplex Biotherapeutics develops a non-engineered autologous cellular therapy for cancer, built on its ENLYST immune cell training platform and lead candidate SUPLEXA, which trains a patient's peripheral blood cells ex vivo to create anti-tumor therapeutic cells. The company operates in the immuno-oncology and cell therapy space and has completed a Phase 1 clinical trial across multiple tumor types.
Founders & leadership
Investors · 3
Also in the syndicate · 2
Reported raises · per SEC filings
Form D private placements$21.1M disclosed across 3 of 4 rounds · 2018–2023
▶$20.7MraisedFeb 2023 · 51 investors · BiotechnologyRule 506(b)
- Francescopalo BorrielloExecutive Officer
- Offering amount
- $25M
- Amount sold
- $20.7M
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$200KraisedJul 2019 · 2 investors · BiotechnologyRule 506(b)
- Francescopaolo BorrielloExecutive Officer, Director
- Amount sold
- $200K
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$200KraisedJan 2019 · 2 investors · BiotechnologyRule 506(b)
- Francescopaolo BorrielloExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $200K
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Alloplex Biotherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Alloplex Biotherapeutics do?
- Alloplex Biotherapeutics develops a non-engineered autologous cellular therapy for cancer, built on its ENLYST immune cell training platform and lead candidate SUPLEXA, which trains a patient's peripheral blood cells ex vivo to create anti-tumor therapeutic cells. The company operates in the immuno-oncology and cell therapy space and has completed a Phase 1 clinical trial across multiple tumor types.
- Who founded Alloplex Biotherapeutics?
- Alloplex Biotherapeutics was founded by Francescopaolo Borriello, Frank Borriello.
- Who are Alloplex Biotherapeutics's investors?
- Alloplex Biotherapeutics's investors include Hackensack Meridian Health Bear's Den.
- How much funding has Alloplex Biotherapeutics raised?
- Alloplex Biotherapeutics has disclosed $21.1M raised across 3 of its 4 known rounds.
- Where is Alloplex Biotherapeutics headquartered?
- Alloplex Biotherapeutics is headquartered in Boston, US.